By Fineline Cube 
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026 financial results, reporting total revenues of RMB 8.141 billion (USD 1.19 billion), representing a 12.98% year-over-year (YOY) increase, and net profits of RMB 2.282 billion (USD 330 million), up 21.78% YOY. The company’s innovative drug sales surged 25.75% to RMB 4.526 billion (USD 660 million), accounting for 61.69% of total pharmaceutical sales, while R&D investment reached RMB 2.224 billion (USD 323 million). The quarter also saw three major regulatory approvals for proprietary Class 1 innovative drugs across oncology and hematology indications.
Financial Performance Summary
| Metric | Q1 2026 | YOY Change |
|---|---|---|
| Total Revenues | RMB 8.141B (USD 1.19B) | +12.98% |
| Net Profits | RMB 2.282B (USD 330M) | +21.78% |
| R&D Investment | RMB 2.224B (USD 323M) | Significant increase |
| Innovative Drug Sales | RMB 4.526B (USD 660M) | +25.75% |
| Oncology Product Sales | RMB 3.313B (USD 481M) | +11.63% |
| Non-Oncology Product Sales | RMB 1.213B (USD 176M) | +92.13% |
| Out-licensing Revenue | RMB 787M (USD 115M) | Strong contribution |
Regulatory Milestones & Pipeline Advancement
- Reltirafusp α Approval: World’s first approved anti-PD-L1/TGF-βRII bispecific antibody (BsAb) fusion protein received marketing approval for first-line treatment of locally advanced unresectable, recurrent or metastatic PD-L1-positive (CPS ≥ 1) gastric or gastroesophageal junction adenocarcinoma in combination with fluoropyrimidine and platinum-based agents
- Trastuzumab Rezetecan Expansion: HER2 ADC Class 1 innovative drug secured additional indication approval for adult patients with locally advanced or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapies
- Hetrombopag Olamine Indication: Class 1 innovative drug gained approval for use in combination with immunosuppressive therapy for newly diagnosed severe aplastic anemia (SAA) in patients aged 15 years and older
- Commercial Impact: These approvals significantly expand Hengrui’s addressable market across gastrointestinal oncology, breast cancer, and rare hematological disorders
Business Segment Analysis
| Segment | Q1 2026 Sales | YOY Growth | Strategic Notes |
|---|---|---|---|
| Total Innovative Drugs | RMB 4.526B | +25.75% | 61.69% of total pharma sales; primary growth driver |
| Oncology Products | RMB 3.313B | +11.63% | 73.20% of innovative drug sales; established franchise |
| Non-Oncology Products | RMB 1.213B | +92.13% | Rapid expansion into new therapeutic areas |
| Out-licensing Revenue | RMB 787M | Strong performance | Validates global partnership strategy and asset quality |
| R&D Investment | RMB 2.224B | 27.3% of revenue | Demonstrates commitment to innovation pipeline |
Strategic Implications
Hengrui’s Q1 2026 performance demonstrates the successful execution of its dual strategy: accelerating commercial momentum in established franchises while expanding into new therapeutic areas through innovative drug development. The 92.13% growth in non-oncology products highlights the company’s successful diversification beyond its traditional oncology stronghold, reducing therapeutic concentration risk.
The three new regulatory approvals represent significant milestones that validate Hengrui’s scientific innovation capabilities and expand its commercial footprint. Reltirafusp α as the world’s first anti-PD-L1/TGF-βRII bispecific antibody positions Hengrui at the forefront of next-generation immuno-oncology, while the trastuzumab rezetecan expansion strengthens its position in the competitive HER2-positive breast cancer market.
The substantial R&D investment of RMB 2.224 billion (27.3% of revenue) underscores Hengrui’s commitment to maintaining a robust innovation pipeline despite strong current commercial performance. This disciplined approach to reinvestment ensures sustainable long-term growth and competitive differentiation in China’s increasingly sophisticated pharmaceutical market.
The RMB 787 million in out-licensing revenue demonstrates the global recognition of Hengrui’s asset quality and validates its international partnership strategy. Such collaborations provide non-dilutive funding for continued R&D while expanding global market access for Hengrui’s innovative therapies.
From a profitability perspective, the 21.78% net profit growth significantly outpacing revenue growth reflects operational leverage, improved product mix toward higher-margin innovative drugs, and effective cost management across the organization.
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, regulatory developments, and business strategy. Actual results may differ due to regulatory decisions, competitive dynamics, market adoption rates, and economic conditions.-Fineline Info & Tech